Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Other Non Operating Income: 2020-2025

Historic Other Non Operating Income for Lyell Immunopharma (LYEL) over the last 6 years, with Sep 2025 value amounting to -$4.9 million.

  • Lyell Immunopharma's Other Non Operating Income fell 11200.00% to -$4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 1949.04%. This contributed to the annual value of $4.7 million for FY2024, which is 154.28% up from last year.
  • Per Lyell Immunopharma's latest filing, its Other Non Operating Income stood at -$4.9 million for Q3 2025, which was down 511.78% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Other Non Operating Income ranged from a high of $4.3 million in Q4 2024 and a low of -$4.9 million during Q3 2025.
  • In the last 3 years, Lyell Immunopharma's Other Non Operating Income had a median value of $1.1 million in 2024 and averaged $379,182.
  • As far as peak fluctuations go, Lyell Immunopharma's Other Non Operating Income surged by 6,768.18% in 2022, and later tumbled by 11,200.00% in 2025.
  • Over the past 5 years, Lyell Immunopharma's Other Non Operating Income (Quarterly) stood at -$44,000 in 2021, then skyrocketed by 6,768.18% to $2.9 million in 2022, then slumped by 117.25% to -$506,000 in 2023, then soared by 948.22% to $4.3 million in 2024, then tumbled by 11,200.00% to -$4.9 million in 2025.
  • Its last three reported values are -$4.9 million in Q3 2025, $1.2 million for Q2 2025, and $1.3 million during Q1 2025.